User menu

Targets for active immunotherapy against pediatric solid tumors

Bibliographic reference Jacobs, Jean-Paul ; Coulie, Pierre ; Figdor, C.G. ; Adema, Gosse J. ; de Vries, I.J.M. ; et. al. Targets for active immunotherapy against pediatric solid tumors. In: Cancer Immunology Immunotherapy, Vol. 58, no. 6, p. 831-841 (2009)
Permanent URL
  1. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC (1998) Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 351:882–883
  2. Aldosari N, Bigner SH, Burger PC, Becker L, Kepner JL, Friedman HS, McLendon RE (2002) MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children’s Oncology Group. Arch Pathol Lab Med 126:540–544
  3. Amir G, Issakov J, Meller I, Sucher E, Peyser A, Cohen IJ, Yaniv I, Ben Arush MW, Tavori U, Kollender Y, Ron N, Peylan-Ramu N (2002) Expression of p53 gene product and cell proliferation marker Ki-67 in Ewing’s sarcoma: correlation with clinical outcome. Hum Pathol 33:170–174
  4. Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, Herlyn M, Parmiani G (1993) Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med 177:989–998
  5. Asemissen AM, Keilholz U, Tenzer S, Muller M, Walter S, Stevanovic S, Schild H, Letsch A, Thiel E, Rammensee HG, Scheibenbogen C (2006) Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1. Clin Cancer Res 12:7476–7482
  6. Ayan I, Dogan O, Kebudi R, Bavbek B, Alatli C, Dervisoglu S, Disci R, Demiryont M (1997) Immunohistochemical detection of p53 protein in rhabdomyosarcoma: association with clinicopathological features and outcome. J Pediatr Hematol Oncol 19:48–53
  7. Baxevanis CN, Sotiriadou NN, Gritzapis AD, Sotiropoulou PA, Perez SA, Cacoullos NT, Papamichail M (2006) Immunogenic HER-2/neu peptides as tumor vaccines. Cancer Immunol Immunother 55:85–95
  8. Bayani J, Zielenska M, Marrano P, Kwan Ng Y, Taylor MD, Jay V, Rutka JT, Squire JA (2000) Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. J Neurosurg 93:437–448
  9. Biagi E, Bollard C, Rousseau R, Brenner M (2003) Gene Therapy for Pediatric Cancer: State of the Art and Future Perspectives. J Biomed Biotechnol 2003:13–24
  10. Bodey B, Bodey B Jr, Siegel SE (1995) Immunophenotypic characterization of infiltrating polynuclear and mononuclear cells in childhood brain tumors. Mod Pathol 8:333–338
  11. Bodey B, Siegel SE, Kaiser HE (2002) MAGE-1, a cancer/testis-antigen, expression in childhood astrocytomas as an indicator of tumor progression. In Vivo 16:583–588
  12. Boon T, Van Snick J, Van Pel A, Uyttenhove C, Marchand M (1980) Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. J Exp Med 152:1184–1193
  13. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337–365
  14. Boon T, Coulie PG, Van den Eynde B (1997) Tumor antigens recognized by T cells. Immunol Today 18:267–268
  15. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P (2006) Human T cell responses against melanoma. Annu Rev Immunol 24:175–208
  16. Bowman L, Grossmann M, Rill D, Brown M, Zhong WY, Alexander B, Leimig T, Coustan-Smith E, Campana D, Jenkins J, Woods D, Kitchingman G, Vanin E, Brenner M (1998) IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood 92:1941–1949
  17. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224:1121–1124
  18. Browett PJ, Cooke HM, Secker-Walker LM, Norton JD (1989) Chromosome 22 breakpoints in variant Philadelphia translocations and Philadelphia-negative chronic myeloid leukemia. Cancer Genet Cytogenet 37:169–177
  19. Caruso DA, Orme LM, Neale AM, Radcliff FJ, Amor GM, Maixner W, Downie P, Hassall TE, Tang ML, Ashley DM (2004) Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro Oncol 6:236–246
  20. Cheung IY, Cheung NK (1997) Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma. Clin Cancer Res 3:821–826
  21. Cheung IY, Cheung NK (2001) Detection of microscopic disease: comparing histology, immunocytology, and RT-PCR of tyrosine hydroxylase, GAGE, and MAGE. Med Pediatr Oncol 36:210–212
  22. Chi DD, Merchant RE, Rand R, Conrad AJ, Garrison D, Turner R, Morton DL, Hoon DS (1997) Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 150:2143–2152
  23. Cooper LJ (2008) Adoptive cellular immunotherapy for childhood malignancies. Bone Marrow Transplant 41:183–192
  24. Coronella J. A., Spier C., Welch M., Trevor K. T., Stopeck A. T., Villar H., Hersh E. M., Antigen-Driven Oligoclonal Expansion of Tumor-Infiltrating B Cells in Infiltrating Ductal Carcinoma of the Breast, 10.4049/jimmunol.169.4.1829
  25. Corrias MV, Scaruffi P, Occhino M, De Bernardi B, Tonini GP, Pistoia V (1996) Expression of MAGE-1, MAGE-3 and MART-1 genes in neuroblastoma. Int J Cancer 69:403–407
  26. Dagher R, Long LM, Read EJ, Leitman SF, Carter CS, Tsokos M, Goletz TJ, Avila N, Berzofsky JA, Helman LJ, Mackall CL (2002) Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol 38:158–164
  27. Dalerba P, Frascella E, Macino B, Mandruzzato S, Zambon A, Rosolen A, Carli M, Ninfo V, Zanovello P (2001) MAGE, BAGE and GAGE gene expression in human rhabdomyosarcomas. Int J Cancer 93:85–90
  28. de Alava E, Antonescu CR, Panizo A, Leung D, Meyers PA, Huvos AG, Pardo-Mindan FJ, Healey JH, Ladanyi M (2000) Prognostic impact of P53 status in Ewing sarcoma. Cancer 89:783–792
  29. De Vleeschouwer S, Van Calenbergh F, Demaerel P, Flamen P, Rutkowski S, Kaempgen E, Wolff JE, Plets C, Sciot R, Van Gool SW (2004) Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report. J Neurosurg 100:492–497
  30. De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, Sciot R, Wilms G, Demaerel P, Warmuth-Metz M, Soerensen N, Wolff JE, Wagner S, Kaempgen E, Van Gool SW (2008) Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 14:3098–3104
  31. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau G (1992) Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359:162–165
  32. Dennis SL, Manji SS, Carrington DP, Scarcella DL, Ashley DM, Smith PJ, Algar EM (2002) Expression and mutation analysis of the Wilms’ tumor 1 gene in human neural tumors. Int J Cancer 97:713–715
  33. Driman D, Thorner PS, Greenberg ML, Chilton-MacNeill S, Squire J (1994) MYCN gene amplification in rhabdomyosarcoma. Cancer 73:2231–2237
  34. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991–998
  35. Engelhard VH, Bullock TN, Colella TA, Sheasley SL, Mullins DW (2002) Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol Rev 188:136–146
  36. Euvrard S, Kanitakis J, Claudy A (2003) Skin cancers after organ transplantation. N Engl J Med 348:1681–1691
  37. Finn OJ (2003) Cancer vaccines: between the idea and the reality. Nat Rev Immunol 3:630–641
  38. Fisk B, Blevins TL, Wharton JT, Ioannides CG (1995) Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181:2109–2117
  39. Foley EJ (1953) Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res 13:835–837
  40. Frost JD, Hank JA, Reaman GH, Frierdich S, Seeger RC, Gan J, Anderson PM, Ettinger LJ, Cairo MS, Blazar BR, Krailo MD, Matthay KK, Reisfeld RA, Sondel PM (1997) A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children’s Cancer Group. Cancer 80:317–333
  41. Gambini C, Sementa AR, Boni L, Marino CE, Croce M, Negri F, Pistoia V, Ferrini S, Corrias MV (2003) Expression of HER2/neu is uncommon in human neuroblastic tumors and is unrelated to tumor progression. Cancer Immunol Immunother 52:116–120
  42. Gandhi MK, Tellam JT, Khanna R (2004) Epstein-Barr virus-associated Hodgkin’s lymphoma. Br J Haematol 125:267–281
  43. Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, Chang AE, Braun TM, Mule JJ (2001) Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 61:8513–8519
  44. Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J (1997) Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 57:3272–3280
  45. Haapasalo H, Hyytinen E, Sallinen P, Helin H, Kallioniemi OP, Isola J, c-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization, 10.1038/bjc.1996.107
  46. Hachitanda Y, Toyoshima S, Akazawa K, Tsuneyoshi M (1998) N-myc gene amplification in rhabdomyosarcoma detected by fluorescence in situ hybridization: its correlation with histologic features. Mod Pathol 11:1222–1227
  47. Hanson HL, Donermeyer DL, Ikeda H, White JM, Shankaran V, Old LJ, Shiku H, Schreiber RD, Allen PM (2000) Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 13:265–276
  48. Himoudi N, Yan M, Papanastasiou A, Anderson J (2008) MYCN as a target for cancer immunotherapy. Cancer Immunol Immunother 57:693–700
  49. Hughes DP, Thomas DG, Giordano TJ, Baker LH, McDonagh KT (2004) Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res 64:2047–2053
  50. Hui AB, Lo KW, Yin XL, Poon WS, Ng HK (2001) Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. Lab Invest 81:717–723
  51. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H (1998) The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188:2357–2368
  52. Ishida H, Matsumura T, Salgaller ML, Ohmizono Y, Kadono Y, Sawada T (1996) MAGE-1 and MAGE-3 or -6 expression in neuroblastoma-related pediatric solid tumors. Int J Cancer 69:375–380
  53. Ito R, Asami S, Motohashi S, Ootsuka S, Yamaguchi Y, Chin M, Shichino H, Yoshida Y, Nemoto N, Mugishima H, Suzuki T (2005) Significance of survivin mRNA expression in prognosis of neuroblastoma. Biol Pharm Bull 28:565–568
  54. Jacobs JF, Brasseur F, Hulsbergen-van de Kaa CA, van de Rakt MW, Figdor CG, Adema GJ, Hoogerbrugge PM, Coulie PG, de Vries IJ (2007) Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. Int J Cancer 120:67–74
  55. Jacobs JF, Hoogerbrugge PM, de Rakt MW, Aarntzen EH, Figdor CG, Adema GJ, de Vries IJ (2007) Phenotypic and functional characterization of mature dendritic cells from pediatric cancer patients. Pediatr Blood Cancer 49:924–927
  56. Jacobs JF, Aarntzen EH, Sibelt LA, Blokx WA, Boullart AC, Gerritsen MJ, Hoogerbrugge PM, Figdor CG, Adema GJ, Punt CJ, de Vries IJ (2008) Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients. Cancer Immunol Immunother 58(1):145–151. doi: 10.1007/s00262-008-0506-5
  57. Jacobs JF, Grauer OM, Brasseur F, Hoogerbrugge PM, Wesseling P, Gidding CE, van de Rakt MW, Figdor CG, Coulie PG, de Vries IJ, Adema GJ (2008) Selective cancer-germline gene expression in pediatric brain tumors. J Neurooncol 88(3):273–280
  58. Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag RM, Mendelow AD, Sengupta RP, Pearson ADJ, Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours, 10.1038/bjc.1992.273
  59. Joshi BH, Leland P, Puri RK (2003) Identification and characterization of interleukin-13 receptor in human medulloblastoma and targeting these receptors with interleukin-13-pseudomonas exotoxin fusion protein. Croat Med J 44:455–462
  60. Kajiwara Y, Yamasaki F, Hama S, Yahara K, Yoshioka H, Sugiyama K, Arita K, Kurisu K (2003) Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer 97:1077–1083
  61. Kalos M (2003) Tumor antigen-specific T cells and cancer immunotherapy: current issues and future prospects. Vaccine 21:781–786
  62. Kalwak K, Ussowicz M, Gorczynska E, Turkiewicz D, Toporski J, Dobaczewski G, Latos-Grazynska E, Ryczan R, Noworolska-Sauren D, Chybicka A (2003) Immunologic effects of intermediate-dose IL-2 i.v. after autologous hematopoietic cell transplantation in pediatric solid tumors. J Interferon Cytokine Res 23:173–181
  63. Karanikas V., Lurquin C., Colau D., van Baren N., De Smet C., Lethe B., Connerotte T., Corbiere V., Demoitie M.-A., Lienard D., Dreno B., Velu T., Boon T., Coulie P. G., Monoclonal Anti-MAGE-3 CTL Responses in Melanoma Patients Displaying Tumor Regression after Vaccination with a Recombinant Canarypox Virus, 10.4049/jimmunol.171.9.4898
  64. Katoh M, Wilmotte R, Belkouch MC, de Tribolet N, Pizzolato G, Dietrich PY (2003) Survivin in brain tumors: an attractive target for immunotherapy. J Neurooncol 64:71–76
  65. Kawakami M, Kawakami K, Takahashi S, Abe M, Puri RK (2004) Analysis of interleukin-13 receptor alpha2 expression in human pediatric brain tumors. Cancer 101:1036–1042
  66. Kershaw MH, Trapani JA, Smyth MJ (1995) Cytotoxic lymphocytes redirecting the cell-mediated immune response for the therapy of cancer. Ther Immunol 2:173–181
  67. Khan J, Bittner ML, Saal LH, Teichmann U, Azorsa DO, Gooden GC, Pavan WJ, Trent JM, Meltzer PS (1999) cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci USA 96:13264–13269
  68. Koehl U, Sorensen J, Esser R, Zimmermann S, Gruttner HP, Tonn T, Seidl C, Seifried E, Klingebiel T, Schwabe D (2004) IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis 33:261–266
  69. Korshunov A, Golanov A, Timirgaz V (2002) Immunohistochemical markers for prognosis of ependymal neoplasms. J Neurooncol 58:255–270
  70. Kuroki M, Shibaguchi H, Imakiire T, Uno K, Shirota K, Higuchi T, Shitama T, Yamada H, Hirose Y, Nagata A (2003) Immunotherapy and gene therapy of cancer using antibodies or their genes against tumor-associated antigens. Anticancer Res 23:4377–4381
  71. Lamont JM, McManamy CS, Pearson AD, Clifford SC, Ellison DW (2004) Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 10:5482–5493
  72. Lampson LA (2003) Brain tumor immunotherapy: an immunologist’s perspective. J Neurooncol 64:3–11
  73. Lang FF, Miller DC, Pisharody S, Koslow M, Newcomb EW (1994) High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas. Oncogene 9:949–954
  74. Larin SS, Georgiev GP, Kiselev SL (2004) Gene transfer approaches in cancer immunotherapy. Gene Ther 11(Suppl 1):S18–S25
  75. Leung W, Hudson MM, Strickland DK, Phipps S, Srivastava DK, Ribeiro RC, Rubnitz JE, Sandlund JT, Kun LE, Bowman LC, Razzouk BI, Mathew P, Shearer P, Evans WE, Pui CH (2000) Late effects of treatment in survivors of childhood acute myeloid leukemia. J Clin Oncol 18:3273–3279
  76. Linet MS, Ries LA, Smith MA, Tarone RE, Devesa SS (1999) Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. J Natl Cancer Inst 91:1051–1058
  77. Liu G, Ying H, Zeng G, Wheeler CJ, Black KL, Yu JS (2004) HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res 64:4980–4986
  78. Ljunggren HG, Malmberg KJ (2007) Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 7:329–339
  79. Lode HN, Pertl U, Xiang R, Gaedicke G, Reisfeld RA (2000) Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma. Med Pediatr Oncol 35:641–646
  80. Lu S, Wang S, Grimes-Serrano JM (2008) Current progress of DNA vaccine studies in humans. Expert Rev Vaccines 7:175–191
  81. Mackall C, Berzofsky J, Helman LJ (2000) Targeting tumor specific translocations in sarcomas in pediatric patients for immunotherapy. Clin Orthop Relat Res 373:25–31
  82. Mackall CL, Rhee EH, Read EJ, Khuu HM, Leitman SF, Bernstein D, Tesso M, Long LM, Grindler D, Merino M, Kopp W, Tsokos M, Berzofsky JA, Helman LJ (2008) A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res 14:4850–4858
  83. Mark HF, Brown S, Sun CL, Samy M, Afify A (1998) Fluorescent in situ hybridization detection of HER-2/neu gene amplification in rhabdomyosarcoma. Pathobiology 66:59–63
  84. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051–3057
  85. Miralbell R, Tolnay M, Bieri S, Probst A, Sappino AP, Berchtold W, Pepper MS, Pizzolato G (1999) Pediatric medulloblastoma: prognostic value of p53, bcl-2, Mib-1, and microvessel density. J Neurooncol 45:103–110
  86. Modak S, Cheung NK (2005) Antibody-based targeted radiation to pediatric tumors. J Nucl Med 46(Suppl 1):157S–163S
  87. Modak S, Cheung NK (2007) Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest 25:67–77
  88. Murray JL, Cunningham JE, Brewer H, Mujoo K, Zukiwski AA, Podoloff DA, Kasi LP, Bhadkamkar V, Fritsche HA, Benjamin RS (1994) Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 12:184–193
  89. Nakachi K, Hayashi T, Imai K, Kusunoki Y (2004) Perspectives on cancer immuno-epidemiology. Cancer Sci 95:921–929
  90. Novellino L, Castelli C, Parmiani G (2005) A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 54:187–207
  91. Oda Y, Wehrmann B, Radig K, Walter H, Rose I, Neumann W, Roessner A (1995) Expression of growth factors and their receptors in human osteosarcomas. Immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: its correlation with proliferating activities and p53 expression. Gen Diagn Pathol 141:97–103
  92. Okada H, Low KL, Kohanbash G, McDonald HA, Hamilton RL, Pollack IF (2008) Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. J Neurooncol 88(3):245–250
  93. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ (1998) Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 187:693–702
  94. Parney IF, Chang LJ (2003) Cancer immunogene therapy: a review. J Biomed Sci 10:37–43
  95. Pavlenko M, Leder C, Pisa P (2005) Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens. Expert Rev Vaccines 4:315–327
  96. Penn I (1988) Tumors of the immunocompromised patient. Annu Rev Med 39:63–73
  97. Pertl U, Wodrich H, Ruehlmann JM, Gillies SD, Lode HN, Reisfeld RA (2003) Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma. Blood 101:649–654
  98. Porter DL, Antin JH (1999) The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med 50:369–386
  99. Ransohoff RM, Kivisakk P, Kidd G (2003) Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 3:569–581
  100. Rickert Christian H., Sträter Ronald, Kaatsch Peter, Wassmann Hansdetlef, Jürgens Heribert, Dockhorn-Dworniczak Barbara, Paulus Werner, Pediatric High-Grade Astrocytomas Show Chromosomal Imbalances Distinct from Adult Cases, 10.1016/s0002-9440(10)64103-x
  101. Ridgway D (2003) The first 1000 dendritic cell vaccinees. Cancer Invest 21:873–886
  102. Rimoldi D, Romero P, Carrel S (1993) The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas. Int J Cancer 54:527–528
  103. Rivoltini L, Arienti F, Orazi A, Cefalo G, Gasparini M, Gambacorti-Passerini C, Fossati-Bellani F, Parmiani G (1992) Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype. Cancer Immunol Immunother 34:241–251
  104. Rodolfo M, Luksch R, Stockert E, Chen YT, Collini P, Ranzani T, Lombardo C, Dalerba P, Rivoltini L, Arienti F, Fossati-Bellani F, Old LJ, Parmiani G, Castelli C (2003) Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen. Cancer Res 63:6948–6955
  105. Rowlinson-Busza G, Epenetos AA (1992) Targeted delivery of biologic and other antineoplastic agents. Curr Opin Oncol 4:1142–1148
  106. Ruggeri L, Mancusi A, Capanni M, Martelli MF, Velardi A (2005) Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr Opin Immunol 17:211–217
  107. Russell HV, Strother D, Mei Z, Rill D, Popek E, Biagi E, Yvon E, Brenner M, Rousseau R (2007) Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J Immunother 30:227–233
  108. Sahin U, Koslowski M, Tureci O, Eberle T, Zwick C, Romeike B, Moringlane JR, Schwechheimer K, Feiden W, Pfreundschuh M (2000) Expression of cancer testis genes in human brain tumors. Clin Cancer Res 6:3916–3922
  109. Sasaki T, Lopes MB, Hankins GR, Helm GA (2002) Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system. Acta Neuropathol (Berl) 104:105–109
  110. Scarcella DL, Chow CW, Gonzales MF, Economou C, Brasseur F, Ashley DM (1999) Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clin Cancer Res 5:335–341
  111. Schwechheimer K, Laufle RM, Schmahl W, Knodlseder M, Fischer H, Hofler H (1994) Expression of neu/c-erbB-2 in human brain tumors. Hum Pathol 25:772–780
  112. Seibel Nita L., Dinndorf Patricia A., Bauer Madeline, Sondel Paul M., Hammond G. Denman, Reaman Gregory H., Phase I Study of Tumor Necrosis Factor-α and Actinomycin D in Pediatric Patients with Cancer : A Childrenʼs Cancer Group Study, 10.1097/00002371-199408000-00006
  113. Seino K, Motohashi S, Fujisawa T, Nakayama T, Taniguchi M (2006) Natural killer T cell-mediated antitumor immune responses and their clinical applications. Cancer Sci 97:807–812
  114. Serraino D, Piselli P, Angeletti C, Scuderi M, Ippolito G, Capobianchi MR (2005) Infection with Epstein-Barr virus and cancer: an epidemiological review. J Biol Regul Homeost Agents 19:63–70
  115. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5:615–625
  116. Sinkovics JG, Horvath JC (2000) Vaccination against human cancers (review). Int J Oncol 16:81–96
  117. Soling A, Schurr P, Berthold F (1999) Expression and clinical relevance of NY-ESO-1, MAGE-1 and MAGE-3 in neuroblastoma. Anticancer Res 19:2205–2209
  118. Sudo T, Kuramoto T, Komiya S, Inoue A, Itoh K (1997) Expression of MAGE genes in osteosarcoma. J Orthop Res 15:128–132
  119. Swann JB, Smyth MJ (2007) Immune surveillance of tumors. J Clin Invest 117:1137–1146
  120. Szybka M, Bartkowiak J, Zakrzewski K, Polis L, Liberski P, Kordek R (2003) Microsatellite instability and expression of DNA mismatch repair genes in malignant astrocytic tumors from adult and pediatric patients. Clin Neuropathol 22:180–186
  121. Takahashi Y, Oda Y, Kawaguchi K, Tamiya S, Yamamoto H, Suita S, Tsuneyoshi M (2004) Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma. Mod Pathol 17:660–669
  122. Trieb K, Lehner R, Stulnig T, Sulzbacher I, Shroyer KR (2003) Survivin expression in human osteosarcoma is a marker for survival. Eur J Surg Oncol 29:379–382
  123. Truitt RL, Piaskowski V, Kirchner P, McOlash L, Camitta BM, Casper JT (1992) Immunological evaluation of pediatric cancer patients receiving recombinant interleukin-2 in a phase I trial. J Immunother 11:274–285
  124. Tsai JY, Aviv H, Benevenia J, Chang VT, Patterson F, Aisner S, Hameed M (2004) HER-2/neu and p53 in osteosarcoma: an immunohistochemical and fluorescence in situ hybridization analysis. Cancer Invest 22:16–24
  125. Tsukahara T, Kawaguchi S, Torigoe T, Asanuma H, Nakazawa E, Shimozawa K, Nabeta Y, Kimura S, Kaya M, Nagoya S, Wada T, Yamashita T, Sato N (2006) Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8–5. Cancer Sci 97:1374–1380
  126. Tweddle Deborah A., Malcolm Archie J., Cole Michael, Pearson Andrew D.J., Lunec John, p53 Cellular Localization and Function in Neuroblastoma, 10.1016/s0002-9440(10)64678-0
  127. Uchi H, Stan R, Turk MJ, Engelhorn ME, Rizzuto GA, Goldberg SM, Wolchok JD, Houghton AN (2006) Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Adv Immunol 90:215–241
  128. Uttenreuther-Fischer MM, Huang CS, Reisfeld RA, Yu AL (1995) Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients. Cancer Immunol Immunother 41:29–36
  129. van den Broeke LT, Pendleton CD, Mackall C, Helman LJ, Berzofsky JA (2006) Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors. Cancer Res 66:1818–1823
  130. van Noesel MM, Versteeg R (2004) Pediatric neuroblastomas: genetic and epigenetic ‘danse macabre’. Gene 325:1–15
  131. Velders MP, Markiewicz MA, Eiben GL, Kast WM (2003) CD4+ T cell matters in tumor immunity. Int Rev Immunol 22:113–140
  132. Vital Anne, Loiseau Hugues, Kantor Guy, Daucourt Valentin, Chene Geneviéve, Cohadon François, Rougier Alain, Rivel Janine, Vital Claude, p53 Protein Expression in Grade II Astrocytomas: Immunohistochemical Study of 100 Cases with Long-Term Follow-Up, 10.1016/s0344-0338(98)80085-x
  133. Vlk V, Eckschlager T, Kavan P, Kabickova E, Koutecky J, Sobota V, Bubenik J, Pospisilova D (2000) Clinical ineffectiveness of IL-2 and/or IFN alpha administration after autologous PBSC transplantation in pediatric oncological patients. Pediatr Hematol Oncol 17:31–44
  134. Ward S, Casey D, Labarthe MC, Whelan M, Dalgleish A, Pandha H, Todryk S (2002) Immunotherapeutic potential of whole tumour cells. Cancer Immunol Immunother 51:351–357
  135. Wolden SL, Lamborn KR, Cleary SF, Tate DJ, Donaldson SS (1998) Second cancers following pediatric Hodgkin’s disease. J Clin Oncol 16:536–544
  136. Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP, Lemonnier FA, Leblond V, Langlade-Demoyen P (1998) Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 101:2290–2296
  137. Yotnda P, Garcia F, Peuchmaur M, Grandchamp B, Duval M, Lemonnier F, Vilmer E, Langlade-Demoyen P (1998) Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. J Clin Invest 102:455–462
  138. Yun C, Senju S, Fujita H, Tsuji Y, Irie A, Matsushita S, Nishimura Y (1999) Augmentation of immune response by altered peptide ligands of the antigenic peptide in a human CD4+ T-cell clone reacting to TEL/AML1 fusion protein. Tissue Antigens 54:153–161
  139. Zhou H, Randall RL, Brothman AR, Maxwell T, Coffin CM, Goldsby RE (2003) Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol 25:27–32